After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

▎药明康德内容团队编辑今日，美国盖伦基金会（TheGalien Foundation）公布了素有“医药界的诺贝尔奖”之称的盖伦奖（PrixGalien USA ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a US national stockpile delivery led to US$2.7 billion in sales for the drug, Pfizer said Tuesday (Oct 29).

It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with ...

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

Pfizer (PFE) reported its third-quarter earnings ... was primarily driven in part to sales from its COVID-19 treatment Paxlovid. The medication was the company’s best-selling drug in the third ...

The Food and Drug Administration (FDA) updated its emergency use authorization (EUA) for Paxlovid (nirmatrelvir/ritonavir) in 2022. This change has allowed people who ...